Certolizumab Pegol and Secukinumab for Treating Active Psoriatic Arthritis Following Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Systematic Review and Economic Evaluation

Citation:

Corbett M, Chehadah F, Biswas M, et al. Health Technol Assess. 2017 Oct;21(56):1-326. PMID: 28976302; PMCID: PMC5641819.